Vilazodone

NERVOUS SYSTEM

Key facts

Vilazodone is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 2011. DrugCentral lists 35 molecular targets, including HTR1A, Htr1a and Slc6a4. Recorded indications include Major depressive disorder.

• Approval status: ofp (first approved 2011 by the FDA).
• Molecular targets: HTR1A, Htr1a, Slc6a4 and SLC6A4 (35 listed in DrugCentral).
• Indications: Major depressive disorder.
• ATC code: N06AX24 (Other antidepressants).
• Molecular formula: C26H27N5O2; molecular weight 441.54 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Major depressive disorder

Contraindications (9)

• Bipolar disorder
• Blood coagulation disorder
• Hyponatremia
• Neuroleptic malignant syndrome
• Seizure disorder
• Serotonin syndrome
• Suicidal
• Suicidal thoughts
• Syndrome of inappropriate vasopressin secretion

Mechanism & targets

Molecular targets (35)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 1A	HTR1A	agonist	Ki 9.70
5-hydroxytryptamine receptor 1A	Htr1a	unknown	IC50 9.52
Sodium-dependent serotonin transporter	Slc6a4	unknown	IC50 9.30
Sodium-dependent serotonin transporter	SLC6A4	inhibitor	IC50 9.30
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 7.85
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 7.19
D(3) dopamine receptor	DRD3	agonist	IC50 7.15
D(3) dopamine receptor	Drd3	unknown	IC50 7.15
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	IC50 6.80
5-hydroxytryptamine receptor 4	Htr4	unknown	IC50 6.60
5-hydroxytryptamine receptor 4	HTR4	agonist	IC50 6.60
Sodium-dependent dopamine transporter	SLC6A3	unknown	IC50 6.53
Histamine H1 receptor	HRH1	agonist	IC50 6.50
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 6.43
D(2) dopamine receptor	DRD2	agonist	IC50 6.18
D(2) dopamine receptor	Drd2	unknown	IC50 6.18
Mu-type opioid receptor	OPRM1	unknown	Ki 6.14
D(4) dopamine receptor	DRD4	unknown	Ki 6.08
5-hydroxytryptamine receptor 6	HTR6	unknown	Ki 6.02
Transmembrane protein 97	TMEM97	unknown	Ki 5.96

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2011-01-21	FDA	—	FOREST LABS LLC

ATC classification

ATC code	Therapeutic hierarchy
N06AX24	NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Suicidal ideation	462.3
Serotonin syndrome	255.3
Abnormal dreams	177.8
Anxiety	151.5
Hallucination	151.3
Completed suicide	145.5
Mania	121.3
Persistent genital arousal disorder	99.8
Agitation	99.0
Anger	91.9
Nightmare	88.4
Tardive dyskinesia	87.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vilazodone is on its molecule page.

• Molecular formula: C₂₆H₂₇N₅O₂
• Molecular weight: 441.54 g/mol
• CAS number: —
• InChIKey: SGEGOXDYSFKCPT-UHFFFAOYSA-N
• PubChem CID: 6918314

NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vilazodone used for?

DrugCentral lists the following indications for Vilazodone: Major depressive disorder.

How does Vilazodone work?

Its molecular targets in DrugCentral include HTR1A (agonist), Htr1a, Slc6a4 and SLC6A4 (inhibitor).

When was Vilazodone first approved?

Vilazodone was first approved by the FDA in 2011.

What is the chemical formula of Vilazodone?

Vilazodone has the molecular formula C26H27N5O2 and a molecular weight of 441.54 g/mol.

Sources

• DrugCentral drug card 4223 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1615374 — compound record and bioactivity
• PubChem CID 6918314 — chemical identifiers
• DrugBank DB06684 — drug record
• FDA UNII S239O2OOV3 — substance identity
• DailyMed: FDA labels for Vilazodone — current prescribing information (label search)
• UniProt P08908 (HTR1A) — target protein
• UniProt P31645 (SLC6A4) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt P41595 (HTR2B) — target protein
• UniProt P35462 (DRD3) — target protein
• UniProt P23975 (SLC6A2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.